Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Cancer Imaging
Published in:

Open Access 01-12-2024 | Review

Seeing through “brain fog”: neuroimaging assessment and imaging biomarkers for cancer-related cognitive impairments

Authors: Quanquan Gu, Liya Wang, Tricia Z. King, Hongbo Chen, Longjiang Zhang, Jianming Ni, Hui Mao

Published in: Cancer Imaging | Issue 1/2024

Login to get access

Abstract

Advances in cancer diagnosis and treatment have substantially improved patient outcomes and survival in recent years. However, up to 75% of cancer patients and survivors, including those with non-central nervous system (non-CNS) cancers, suffer from “brain fog” or impairments in cognitive functions such as attention, memory, learning, and decision-making. While we recognize the impact of cancer-related cognitive impairment (CRCI), we have not fully investigated and understood the causes, mechanisms and interplays of various involving factors. Consequently, there are unmet needs in clinical oncology in assessing the risk of CRCI and managing patients and survivors with this condition in order to make informed treatment decisions and ensure the quality of life for cancer survivors. The state-of-the-art neuroimaging technologies, particularly clinical imaging modalities like magnetic resonance imaging (MRI) and positron emission tomography (PET), have been widely used to study neuroscience questions, including CRCI. However, in-depth applications of these functional and molecular imaging methods in CRCI and their clinical implementation for CRCI management are largely limited. This scoping review provides the current understanding of contributing neurological factors to CRCI and applications of the state-of-the-art multi-modal neuroimaging methods in investigating the functional and structural alterations related to CRCI. Findings from these studies and potential imaging-biomarkers of CRCI that can be used to improve the assessment and characterization of CRCI as well as to predict the risk of CRCI are also highlighted. Emerging issues and perspectives on future development and applications of neuroimaging tools to better understand CRCI and incorporate neuroimaging-based approaches to treatment decisions and patient management are discussed.
Literature
1.
Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health interview survey. Cancer Epidemiol Biomarkers Prev. 2012;21(11):2108–17.PubMedPubMedCentralCrossRef
2.
Henneghan AM, Van Dyk K, Kaufmann T, Harrison R, Gibbons C, Heijnen C, et al. Measuring self-reported Cancer-related cognitive impairment: recommendations from the Cancer Neuroscience Initiative Working Group. J Natl Cancer Inst. 2021;113(12):1625–33.PubMedPubMedCentralCrossRef
3.
Horowitz TS, Suls J, Trevino M. A call for a Neuroscience Approach to Cancer-related cognitive impairment. Trends Neurosci. 2018;41(8):493–6.PubMedCrossRef
4.
Zhang DF, Ma H, Yang GJ, Zhang ZP, He YF, Feng MY, et al. Blood-brain barrier and brain structural changes in lung cancer patients with non-brain metastases. Front Oncol. 2022;12:1015011.PubMedPubMedCentralCrossRef
5.
Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925–40.PubMedCrossRef
6.
Mandelblatt JS, Hurria A, McDonald BC, Saykin AJ, Stern RA, VanMeter JW, et al. Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know? Semin Oncol. 2013;40(6):709–25.PubMedCrossRef
7.
Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the silver tsunami: prevalence trajectories and Comorbidity Burden among Older Cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev. 2016;25(7):1029–36.PubMedPubMedCentralCrossRef
8.
Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28(29):4434–40.PubMedPubMedCentralCrossRef
9.
Wu LM, Amidi A. Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients. Curr Opin Support Palliat Care. 2017;11(1):38–45.PubMedPubMedCentralCrossRef
10.
Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, et al. Course and predictors of cognitive function in patients with prostate Cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33(18):2021–7.PubMedPubMedCentralCrossRef
11.
Kautiainen R, Aleksonis H, King TZ. A systematic review of host genomic variation and neuropsychological outcomes for Pediatric Cancer survivors. Neuropsychol Rev. 2023;33(1):278–306.PubMedCrossRef
12.
Oppegaard KR, Armstrong TS, Anguera JA, Kober KM, Kelly DL, Laister RC, et al. Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: a scoping review. Crit Rev Oncol Hematol. 2022;180:103822.PubMedCrossRef
13.
Fernandez HR, Varma A, Flowers SA, Rebeck GW. Cancer chemotherapy related cognitive impairment and the impact of the Alzheimer’s disease risk factor APOE. Cancers (Basel). 2020;12(12):3842.
14.
15.
Cheng H, Li W, Gan C, Zhang B, Jia Q, Wang K. The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am J Transl Res. 2016;8(11):5087–97.PubMedPubMedCentral
16.
Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav. 2006;5(4):311–28.PubMedCrossRef
17.
Small BJ, Rawson KS, Walsh E, Jim HS, Hughes TF, Iser L, et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer. 2011;117(7):1369–76.PubMedCrossRef
18.
Williams AM, Shah R, Shayne M, Huston AJ, Krebs M, Murray N, et al. Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy. J Neuroimmunol. 2018;314:17–23.PubMedCrossRef
19.
Schagen SB, Tsvetkov AS, Compter A, Wefel JS. Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach? Nat Rev Neurol. 2022;18(3):173–85.PubMedCrossRef
20.
Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8(11):887–99.PubMedCrossRef
21.
Wardill HR, Mander KA, Van Sebille YZ, Gibson RJ, Logan RM, Bowen JM, et al. Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. Int J Cancer. 2016;139(12):2635–45.PubMedCrossRef
22.
Dias-Carvalho A, Ferreira M, Ferreira R, Bastos ML, Sa SI, Capela JP, et al. Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events. Arch Toxicol. 2022;96(1):11–78.PubMedCrossRef
23.
Krasnow SM, Knoll JG, Verghese SC, Levasseur PR, Marks DL. Amplification and propagation of interleukin-1beta signaling by murine brain endothelial and glial cells. J Neuroinflammation. 2017;14(1):133.PubMedPubMedCentralCrossRef
24.
Zenaro E, Pietronigro E, Della Bianca V, Piacentino G, Marongiu L, Budui S, et al. Neutrophils promote Alzheimer’s disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med. 2015;21(8):880–6.PubMedCrossRef
25.
Varvel NH, Neher JJ, Bosch A, Wang W, Ransohoff RM, Miller RJ, et al. Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus. Proc Natl Acad Sci U S A. 2016;113(38):E5665–74.PubMedPubMedCentralCrossRef
26.
Burfeind KG, Zhu X, Norgard MA, Levasseur PR, Huisman C, Buenafe AC, et al. Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer. Elife. 2020;9:e54095.
27.
Hoeffner EG. Central Nervous System complications of oncologic therapy. Hematol Oncol Clin North Am. 2016;30(4):899–920.PubMedCrossRef
28.
Briones TL, Woods J. Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci. 2011;12:124.PubMedPubMedCentralCrossRef
29.
Zajaczkowska R, Kocot-Kepska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019;20(6):1451.
30.
Seigers R, Timmermans J, van der Horn HJ, de Vries EF, Dierckx RA, Visser L, et al. Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res. 2010;207(2):265–72.PubMedCrossRef
31.
Parikh S. The neurologic manifestations of mitochondrial disease. Dev Disabil Res Rev. 2010;16(2):120–8.PubMedCrossRef
32.
Wang C, Zhao Y, Wang L, Pan S, Liu Y, Li S, et al. C-phycocyanin mitigates cognitive impairment in Doxorubicin-Induced Chemobrain: impact on Neuroinflammation, oxidative stress, and Brain mitochondrial and synaptic alterations. Neurochem Res. 2021;46(2):149–58.PubMedCrossRef
33.
Weymann KB, Wood LJ, Zhu X, Marks DL. A role for orexin in cytotoxic chemotherapy-induced fatigue. Brain Behav Immun. 2014;37:84–94.PubMedCrossRef
34.
Wagner LI, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, et al. Patient-reported cognitive impairment among women with early breast Cancer randomly assigned to endocrine therapy alone Versus Chemoendocrine Therapy: results from TAILORx. J Clin Oncol. 2020;38(17):1875–86.PubMedPubMedCentralCrossRef
35.
Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, et al. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. Psychooncology. 2012;21(5):479–87.PubMedCrossRef
36.
Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM, et al. Patterns of change in cognitive function with anastrozole therapy. Cancer. 2015;121(15):2627–36.PubMedCrossRef
37.
Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28(8):1294–300.PubMedCrossRef
38.
Merriman JD, Von Ah D, Miaskowski C, Aouizerat BE. Proposed mechanisms for cancer- and treatment-related cognitive changes. Semin Oncol Nurs. 2013;29(4):260–9.PubMedCrossRef
39.
McGinty HL, Phillips KM, Jim HS, Cessna JM, Asvat Y, Cases MG, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271–80.PubMedPubMedCentralCrossRef
40.
Jayadevappa R, Chhatre S, Malkowicz SB, Parikh RB, Guzzo T, Wein AJ. Association between Androgen Deprivation Therapy Use and diagnosis of dementia in men with prostate Cancer. JAMA Netw Open. 2019;2(7):e196562.PubMedPubMedCentralCrossRef
41.
Plata-Bello J, Plata-Bello A, Perez-Martin Y, Fajardo V, Concepcion-Massip T. Androgen deprivation therapy increases brain ageing. Aging. 2019;11(15):5613–27.PubMedPubMedCentralCrossRef
42.
Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5):1097–106.PubMedCrossRef
43.
Joly F, Heutte N, Duclos B, Noal S, Leger-Hardy I, Dauchy S, et al. Prospective evaluation of the impact of antiangiogenic treatment on cognitive functions in metastatic renal Cancer. Eur Urol Focus. 2016;2(6):642–9.PubMedCrossRef
44.
Ng T, Cheung YT, Ng QS, Ho HK, Chan A. Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies. Expert Opin Drug Saf. 2014;13(1):83–92.PubMedCrossRef
45.
McGinnis GJ, Friedman D, Young KH, Torres ER, Thomas CR Jr., Gough MJ, et al. Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget. 2017;8(6):9155–73.PubMedCrossRef
46.
Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, et al. Cognitive function in patients with Colorectal Cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33(34):4085–92.PubMedPubMedCentralCrossRef
47.
Kim YK, Na KS, Myint AM, Leonard BE. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:277–84.PubMedCrossRef
48.
Zhu B, Dong Y, Xu Z, Gompf HS, Ward SA, Xue Z, et al. Sleep disturbance induces neuroinflammation and impairment of learning and memory. Neurobiol Dis. 2012;48(3):348–55.PubMedPubMedCentralCrossRef
49.
Hampson JP, Zick SM, Khabir T, Wright BD, Harris RE. Altered resting brain connectivity in persistent cancer related fatigue. Neuroimage Clin. 2015;8:305–13.PubMedPubMedCentralCrossRef
50.
Schagen SB, Das E, Vermeulen I. Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients. Psychooncology. 2012;21(10):1132–5.PubMedCrossRef
51.
Biglia N, Bounous VE, Malabaila A, Palmisano D, Torta DM, D’Alonzo M, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl). 2012;21(4):485–92.PubMedCrossRef
52.
Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26(7):955–69.PubMedCrossRef
53.
Krolak D, Collins B, Weiss L, Harris C, Van der Jagt R. Cognitive function and its relationship to other psychosocial factors in lymphoma survivors. Support Care Cancer. 2017;25(3):905–13.PubMedCrossRef
54.
Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage. 2004;21(1):364–71.PubMedCrossRef
55.
Ranganath C, Ritchey M. Two cortical systems for memory-guided behaviour. Nat Rev Neurosci. 2012;13(10):713–26.PubMedCrossRef
56.
Poppenk J, Moscovitch M. A hippocampal marker of recollection memory ability among healthy young adults: contributions of posterior and anterior segments. Neuron. 2011;72(6):931–7.PubMedCrossRef
57.
McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Gray Matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123(3):819–28.PubMedPubMedCentralCrossRef
58.
Amidi A, Agerbaek M, Wu LM, Pedersen AD, Mehlsen M, Clausen CR, et al. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav. 2017;11(3):769–83.PubMedCrossRef
59.
McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl0):S117–25.PubMedCrossRef
60.
Jenkins V, Thwaites R, Cercignani M, Sacre S, Harrison N, Whiteley-Jones H, et al. A feasibility study exploring the role of pre-operative assessment when examining the mechanism of ‘chemo-brain’ in breast cancer patients. Springerplus. 2016;5:390.PubMedPubMedCentralCrossRef
61.
Lepage C, Smith AM, Moreau J, Barlow-Krelina E, Wallis N, Collins B, et al. A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. Springerplus. 2014;3:444.PubMedPubMedCentralCrossRef
62.
de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33(12):2971–83.PubMedCrossRef
63.
Simo M, Vaquero L, Ripolles P, Gurtubay-Antolin A, Jove J, Navarro A, et al. Longitudinal brain changes Associated with prophylactic cranial irradiation in Lung Cancer. J Thorac Oncol. 2016;11(4):475–86.PubMedCrossRef
64.
de Ruiter MB, Deardorff RL, Blommaert J, Chen BT, Dumas JA, Schagen SB, et al. Brain gray matter reduction and premature brain aging after breast cancer chemotherapy: a longitudinal multicenter data pooling analysis. Brain Imaging Behav. 2023;17(5):507–18.
65.
Feng Y, Zhang XD, Zheng G, Zhang LJ. Chemotherapy-induced brain changes in breast cancer survivors: evaluation with multimodality magnetic resonance imaging. Brain Imaging Behav. 2019;13(6):1799–814.PubMedCrossRef
66.
Nekhlyudov L, Campbell GB, Schmitz KH, Brooks GA, Kumar AJ, Ganz PA, et al. Cancer-related impairments and functional limitations among long-term cancer survivors: gaps and opportunities for clinical practice. Cancer. 2022;128(2):222–9.PubMedCrossRef
67.
Li M, Caeyenberghs K. Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review. Neurosci Biobehav Rev. 2018;92:304–17.PubMedCrossRef
68.
Correa DD, Root JC, Kryza-Lacombe M, Mehta M, Karimi S, Hensley ML, et al. Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study. Brain Imaging Behav. 2017;11(6):1652–63.PubMedPubMedCentralCrossRef
69.
Billiet T, Emsell L, Vandenbulcke M, Peeters R, Christiaens D, Leemans A, et al. Recovery from chemotherapy-induced white matter changes in young breast cancer survivors? Brain Imaging Behav. 2018;12(1):64–77.PubMedCrossRef
70.
Koppelmans V, de Groot M, de Ruiter MB, Boogerd W, Seynaeve C, Vernooij MW, et al. Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Hum Brain Mapp. 2014;35(3):889–99.PubMedCrossRef
71.
Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109(1):146–56.PubMedCrossRef
72.
Lv P, Ma G, Chen W, Liu R, Xin X, Lu J, et al. Brain morphological alterations and their correlation to tumor differentiation and duration in patients with lung cancer after platinum chemotherapy. Front Oncol. 2022;12:903249.PubMedPubMedCentralCrossRef
73.
Daniel E, Deng F, Patel SK, Sedrak MS, Kim H, Razavi M, et al. Cortical thinning in chemotherapy-treated older long-term breast cancer survivors. Brain Imaging Behav. 2023;17(1):66–76.PubMedCrossRef
74.
Blommaert J, Schroyen G, Vandenbulcke M, Radwan A, Smeets A, Peeters R, et al. Age-dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. Hum Brain Mapp. 2019;40(17):4994–5010.PubMedPubMedCentralCrossRef
75.
Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000;97(20):11050–5.PubMedPubMedCentralCrossRef
76.
Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. NeuroImage. 1999;9(2):179–94.PubMedCrossRef
77.
McDonald BC, Van Dyk K, Deardorff RL, Bailey JN, Zhai W, Carroll JE, et al. Multimodal MRI examination of structural and functional brain changes in older women with breast cancer in the first year of antiestrogen hormonal therapy. Breast Cancer Res Treat. 2022;194(1):113–26.PubMedPubMedCentralCrossRef
78.
Spalthoff R, Gaser C, Nenadic I. Altered gyrification in schizophrenia and its relation to other morphometric markers. Schizophr Res. 2018;202:195–202.PubMedCrossRef
79.
Madan CR. Age-related decrements in cortical gyrification: evidence from an accelerated longitudinal dataset. Eur J Neurosci. 2021;53(5):1661–71.PubMedCrossRef
80.
Daniel E, Deng F, Patel SK, Sedrak MS, Kim H, Razavi M, et al. Altered gyrification in chemotherapy-treated older long-term breast cancer survivors. Brain Behav. 2024;14(8):e3634.
81.
Doucet GE, Hamlin N, Kruse JA, Taylor BK, Poirel N. Link between fluid/crystallized intelligence and global/local visual abilities across adulthood. Conscious Cogn. 2022;106:103429.PubMedPubMedCentralCrossRef
82.
83.
Supekar K, Menon V, Rubin D, Musen M, Greicius MD. Network analysis of intrinsic functional brain connectivity in Alzheimer’s disease. PLoS Comput Biol. 2008;4(6):e1000100.PubMedPubMedCentralCrossRef
84.
Kesler SR, Rao V, Ray WJ, Rao A, Alzheimer’s Disease Neuroimaging I. Probability of Alzheimer’s disease in breast cancer survivors based on gray-matter structural network efficiency. Alzheimers Dement (Amst). 2017;9:67–75.PubMedCrossRef
85.
Pierpaoli C, Jezzard P, Basser PJ, Barnett A, Di Chiro G. Diffusion tensor MR imaging of the human brain. Radiology. 1996;201(3):637–48.PubMedCrossRef
86.
Brown MS, Stemmer SM, Simon JH, Stears JC, Jones RB, Cagnoni PJ, et al. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. AJNR Am J Neuroradiol. 1998;19(2):217–21.PubMedPubMedCentral
87.
Stemmer SM, Stears JC, Burton BS, Jones RB, Simon JH. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. AJNR Am J Neuroradiol. 1994;15(7):1267–73.PubMedPubMedCentral
88.
King TZ, Wang L, Mao H. Disruption of White Matter Integrity in Adult survivors of Childhood Brain tumors: correlates with long-term intellectual outcomes. PLoS ONE. 2015;10(7):e0131744.PubMedPubMedCentralCrossRef
89.
Na S, Li L, Crosson B, Dotson V, MacDonald TJ, Mao H, et al. White matter network topology relates to cognitive flexibility and cumulative neurological risk in adult survivors of pediatric brain tumors. Neuroimage Clin. 2018;20:485–97.PubMedPubMedCentralCrossRef
90.
Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Van den Stock J, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp. 2011;32(3):480–93.PubMedCrossRef
91.
Li TY, Chen VC, Yeh DC, Huang SL, Chen CN, Chai JW, et al. Investigation of chemotherapy-induced brain structural alterations in breast cancer patients with generalized q-sampling MRI and graph theoretical analysis. BMC Cancer. 2018;18(1):1211.PubMedPubMedCentralCrossRef
92.
Simo M, Root JC, Vaquero L, Ripolles P, Jove J, Ahles T, et al. Cognitive and brain structural changes in a lung cancer population. J Thorac Oncol. 2015;10(1):38–45.PubMedPubMedCentralCrossRef
93.
Stouten-Kemperman MM, de Ruiter MB, Koppelmans V, Boogerd W, Reneman L, Schagen SB. Neurotoxicity in breast cancer survivors >/=10 years post-treatment is dependent on treatment type. Brain Imaging Behav. 2015;9(2):275–84.PubMedCrossRef
94.
Kesler SR, Watson CL, Blayney DW. Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. Neurobiol Aging. 2015;36(8):2429–42.PubMedPubMedCentralCrossRef
95.
Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25(25):3866–70.PubMedCrossRef
96.
Wang L, Apple AC, Schroeder MP, Ryals AJ, Voss JL, Gitelman D, et al. Reduced prefrontal activation during working and long-term memory tasks and impaired patient-reported cognition among cancer survivors postchemotherapy compared with healthy controls. Cancer. 2016;122(2):258–68.PubMedCrossRef
97.
Pergolizzi D, Root JC, Pan H, Silbersweig D, Stern E, Passik SD, et al. Episodic memory for visual scenes suggests compensatory brain activity in breast cancer patients: a prospective longitudinal fMRI study. Brain Imaging Behav. 2019;13(6):1674–88.PubMedPubMedCentralCrossRef
98.
Saward JB, Ellis EG, Cobden AL, Caeyenberghs K. Mapping cognitive deficits in cancer patients after chemotherapy: an activation likelihood estimation meta-analysis of task-related fMRI studies. Brain Imaging Behav. 2022;16(5):2320–34.PubMedPubMedCentralCrossRef
99.
de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FS, Nederveen AJ, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206–19.PubMedCrossRef
100.
Kesler SR, Adams M, Packer M, Rao V, Henneghan AM, Blayney DW, et al. Disrupted brain network functional dynamics and hyper-correlation of structural and functional connectome topology in patients with breast cancer prior to treatment. Brain Behav. 2017;7(3):e00643.PubMedPubMedCentralCrossRef
101.
McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol. 2012;30(20):2500–8.PubMedPubMedCentralCrossRef
102.
Menning S, de Ruiter MB, Veltman DJ, Koppelmans V, Kirschbaum C, Boogerd W, et al. Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment–the role of fatigue. Neuroimage Clin. 2015;7:547–54.PubMedPubMedCentralCrossRef
103.
Miao H, Li J, Hu S, He X, Partridge SC, Ren J, et al. Long-term cognitive impairment of breast cancer patients after chemotherapy: a functional MRI study. Eur J Radiol. 2016;85(6):1053–7.PubMedCrossRef
104.
Buckner RL, Andrews-Hanna JR, Schacter DL. The brain’s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1–38.PubMedCrossRef
105.
Correa DD, Vachha BA, Baser RE, Koch A, Wong P, Gohel S, et al. Neuroimaging and neurocognitive outcomes in older patients with multiple myeloma treated with chemotherapy and autologous stem cell transplantation. Cancers (Basel). 2023;15(18):4484.
106.
Dumas JA, Makarewicz J, Schaubhut GJ, Devins R, Albert K, Dittus K, et al. Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study. Brain Imaging Behav. 2013;7(4):524–32.PubMedCrossRef
107.
Bromis K, Gkiatis K, Karanasiou I, Matsopoulos G, Karavasilis E, Papathanasiou M, et al. Altered Brain Functional Connectivity in Small-Cell Lung Cancer patients after Chemotherapy Treatment: a resting-state fMRI study. Comput Math Methods Med. 2017;2017:1403940.PubMedPubMedCentralCrossRef
108.
Klaassens BL, van Gerven JMA, van der Grond J, de Vos F, Moller C, Rombouts S. Diminished posterior Precuneus Connectivity with the default Mode Network differentiates normal aging from Alzheimer’s Disease. Front Aging Neurosci. 2017;9:97.PubMedPubMedCentralCrossRef
109.
Mounier NM, Abdel-Maged AE, Wahdan SA, Gad AM, Azab SS. Chemotherapy-induced cognitive impairment (CICI): an overview of etiology and pathogenesis. Life Sci. 2020;258:118071.PubMedCrossRef
110.
Kesler SR, Blayney DW. Neurotoxic effects of Anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast Cancer survivors. JAMA Oncol. 2016;2(2):185–92.PubMedPubMedCentralCrossRef
111.
Feng Y, Wang YF, Zheng LJ, Shi Z, Huang W, Zhang LJ. Network-level functional connectivity alterations in chemotherapy treated breast cancer patients: a longitudinal resting state functional MRI study. Cancer Imaging. 2020;20(1):73.PubMedPubMedCentralCrossRef
112.
Petrella JR. Use of graph theory to evaluate brain networks: a clinical tool for a small world? Radiology. 2011;259(2):317–20.PubMedCrossRef
113.
Bullmore ET, Bassett DS. Brain graphs: graphical models of the human brain connectome. Annu Rev Clin Psychol. 2011;7:113–40.PubMedCrossRef
114.
115.
Lago-Fernandez LF, Huerta R, Corbacho F, Siguenza JA. Fast response and temporal coherent oscillations in small-world networks. Phys Rev Lett. 2000;84(12):2758–61.PubMedCrossRef
116.
Power JD, Schlaggar BL, Lessov-Schlaggar CN, Petersen SE. Evidence for hubs in human functional brain networks. Neuron. 2013;79(4):798–813.PubMedCrossRef
117.
Bruno J, Hosseini SM, Kesler S. Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis. 2012;48(3):329–38.PubMedPubMedCentralCrossRef
118.
Kesler SR, Rao A, Blayney DW, Oakley-Girvan IA, Karuturi M, Palesh O. Predicting Long-Term Cognitive Outcome following breast Cancer with pre-treatment resting state fMRI and Random Forest Machine Learning. Front Hum Neurosci. 2017;11:555.PubMedPubMedCentralCrossRef
119.
120.
Chiaravalloti A, Filippi L, Pagani M, Schillaci O. Functional imaging of Chemobrain: usefulness of Nuclear Medicine in the fog coming after Cancer. J Nucl Med. 2023;64(4):508–14.PubMedCrossRef
121.
Prosser AMJ, Tossici-Bolt L, Kipps CM. The impact of regional (99m)Tc-HMPAO single-photon-emission computed tomography (SPECT) imaging on clinician diagnostic confidence in a mixed cognitive impairment sample. Clin Radiol. 2020;75(9):714. e7- e14.CrossRef
122.
Yamamoto R, Takenoshita N, Inagawa Y, Kato H, Kaneshiro K, Kamiya T, et al. Association between longitudinal changes in striatal dopamine transporter uptake and clinical features of dementia with Lewy bodies. Psychogeriatrics. 2023;23(6):1036–42.PubMedCrossRef
123.
Carlson BW, Craft MA, Carlson JR, Razaq W, Deardeuff KK, Benbrook DM. Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. Geroscience. 2018;40(3):325–36.PubMedPubMedCentralCrossRef
124.
Vera P, Rohrlich P, Stievenart JL, Elmaleh M, Duval M, Bonnin F, et al. Contribution of single-photon emission computed tomography in the diagnosis and follow-up of CNS toxicity of a cytarabine-containing regimen in pediatric leukemia. J Clin Oncol. 1999;17(9):2804–10.PubMedCrossRef
125.
Vitor T, Kozasa EH, Bressan RA, Lacerda SS, Campos Neto GC, Batista IR, et al. Impaired brain dopamine transporter in chemobrain patients submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1. Ann Nucl Med. 2019;33(4):269–79.PubMedCrossRef
126.
Tong T, Lu H, Zong J, Lv Q, Chu X. Chemotherapy-related cognitive impairment in patients with breast cancer based on MRS and DTI analysis. Breast Cancer. 2020;27(5):893–902.PubMedCrossRef
127.
Schroyen G, Schramm G, Van Weehaeghe D, Leenaerts N, Vande Casteele T, Blommaert J, et al. Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue. Front Oncol. 2022;12:1021615.PubMedPubMedCentralCrossRef
128.
Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103(3):303–11.PubMedCrossRef
129.
Baudino B, D’Agata F, Caroppo P, Castellano G, Cauda S, Manfredi M, et al. The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol Imaging. 2012;56(6):559–68.PubMed
130.
Filippi L, Schillaci O, Palumbo B. Neuroimaging with PET/CT in chronic traumatic encephalopathy: what nuclear medicine can do to move the field forward. Expert Rev Mol Diagn. 2022;22(2):149–56.PubMedCrossRef
131.
Schroyen G, Blommaert J, van Weehaeghe D, Sleurs C, Vandenbulcke M, Dedoncker N, et al. Neuroinflammation and its Association with Cognition, neuronal markers and peripheral inflammation after chemotherapy for breast Cancer. Cancers (Basel). 2021;13(16):4198.
132.
Buonocore MH, Maddock RJ. Magnetic resonance spectroscopy of the brain: a review of physical principles and technical methods. Rev Neurosci. 2015;26(6):609–32.PubMedCrossRef
133.
Kesler S, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(Suppl0):S109–16.PubMedCrossRef
134.
Chiappelli J, Hong LE, Wijtenburg SA, Du X, Gaston F, Kochunov P, et al. Alterations in frontal white matter neurochemistry and microstructure in schizophrenia: implications for neuroinflammation. Transl Psychiatry. 2015;5(4):e548.PubMedPubMedCentralCrossRef
135.
Huang BY, Kwock L, Castillo M, Smith JK. Association of choline levels and tumor perfusion in brain metastases assessed with proton MR spectroscopy and dynamic susceptibility contrast-enhanced perfusion weighted MRI. Technol Cancer Res Treat. 2010;9(4):327–37.PubMedCrossRef
136.
Kesler SR, Watson C, Koovakkattu D, Lee C, O’Hara R, Mahaffey ML, et al. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav. 2013;7(4):501–10.PubMedCrossRef
137.
Arefhosseini S, Roshanravan N, Asghari S, Tutunchi H, Ebrahimi-Mameghani M. Expression of inflammatory genes, WBC-derived inflammatory biomarkers and liver function indices: effects of myo-inositol supplementation in obese patients with NAFLD. J Funct Foods. 2023;104:105524.
138.
Haroon E, Chen X, Li Z, Patel T, Woolwine BJ, Hu XP, et al. Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia. Transl Psychiatry. 2018;8(1):189.PubMedPubMedCentralCrossRef
139.
140.
Harris WJ, Asselin MC, Hinz R, Parkes LM, Allan S, Schiessl I, et al. In vivo methods for imaging blood-brain barrier function and dysfunction. Eur J Nucl Med Mol Imaging. 2023;50(4):1051–83.PubMedCrossRef
141.
Moyaert P, Padrela BE, Morgan CA, Petr J, Versijpt J, Barkhof F, et al. Imaging blood-brain barrier dysfunction: a state-of-the-art review from a clinical perspective. Front Aging Neurosci. 2023;15:1132077.PubMedPubMedCentralCrossRef
142.
Varatharaj A, Liljeroth M, Darekar A, Larsson HBW, Galea I, Cramer SP. Blood-brain barrier permeability measured using dynamic contrast-enhanced magnetic resonance imaging: a validation study. J Physiol. 2019;597(3):699–709.PubMedCrossRef
143.
Zhang DF, Li ZH, Zhang ZP, He YF, Shang BL, Xu XF, et al. Cognitive changes are associated with increased blood-brain barrier leakage in non-brain metastases lung cancer patients. Brain Imaging Behav. 2023;17(1):90–9.PubMedCrossRef
144.
Telischak NA, Detre JA, Zaharchuk G. Arterial spin labeling MRI: clinical applications in the brain. J Magn Reson Imaging. 2015;41(5):1165–80.PubMedCrossRef
145.
Nudelman KN, Wang Y, McDonald BC, Conroy SK, Smith DJ, West JD, et al. Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS ONE. 2014;9(5):e96713.PubMedPubMedCentralCrossRef
146.
Franco-Rocha OY, Lewis KA, Longoria KD, De La Torre Schutz A, Wright ML, Kesler SR. Cancer-related cognitive impairment in racial and ethnic minority groups: a scoping review. J Cancer Res Clin Oncol. 2023;149(13):12561–87.PubMedCrossRef
147.
Peterson RK, King TZ. A systematic review of pediatric neuropsychological outcomes with proton versus photon radiation therapy: a call for equity in access to treatment. J Int Neuropsychol Soc. 2023;29(8):798–811.PubMedCrossRef
Metadata
Title
Seeing through “brain fog”: neuroimaging assessment and imaging biomarkers for cancer-related cognitive impairments
Authors
Quanquan Gu
Liya Wang
Tricia Z. King
Hongbo Chen
Longjiang Zhang
Jianming Ni
Hui Mao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2024
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-024-00797-2

Other articles of this Issue 1/2024

Contrast-enhanced ultrasonography–CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome

Nuclear medicine imaging in non-seminomatous germ cell tumors: lessons learned from the past failures

  • Open Access
  • Review

Radiomics nomogram based on CT radiomics features and clinical factors for prediction of Ki-67 expression and prognosis in clear cell renal cell carcinoma: a two-center study

  • Open Access
  • Research article

A CT-based radiomics nomogram for predicting histologic grade and outcome in chondrosarcoma

Predicting first-line VEGFR-TKI resistance and survival in metastatic clear cell renal cell carcinoma using a clinical-radiomic nomogram

  • Open Access
  • Research

Dual-energy computed tomography in a multiparametric regression model for diagnosing lymph node metastases in pancreatic ductal adenocarcinoma

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits